Abstract:Background Metabolic dysfunction-associated steatotic liver disease (MASLD) imposes a substantial global disease burden. This study aims to elucidate the role of intestinal NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome in the gut-liver axis and provide novel insights for potential therapeutic targets. Methods Mice were fed with a methionine-choline deficient (MCD) diet for four weeks to induce MASLD models. Nlrp3fl/fl and Vil1creNlrp3fl/fl mice, with a specific knockout of NLRP3 in intestinal epithelial cells, were housed either separately or together to establish models for MASLD. Liver and intestinal tissues were collected for the assessment of hepatic steatosis, inflammation, fibrosis, and integrity of the intestinal mucosal barrier, while fecal microbiota composition was analyzed using 16S rDNA sequencing. The in vivo effects of intragastric butyrate were evaluated using Vil1creNlrp3fl/fl-MCD mice. Results Wild-type (WT)-MCD mice exhibited exacerbated hepatic steatosis and reduced intestinal NLRP3 mRNA expression compared to WT mice fed with a methionine-choline sufficient (MCS) diet, suggesting a protective role of intestinal NLRP3. The Vil1creNlrp3fl/fl-MCD vs. Nlrp3fl/fl-MCD mice exhibited elevated hepatic lipid deposition and increased expression of α-SMA. Additionally, they displayed compromised intestinal mucosal barrier function characterized by shortened villi, reduced goblet cell count, and decreased expression of Reg3a and Cldn7. The co-housed Vil1creNlrp3fl/fl-MCD with Nlrp3fl/fl-MCD mice showed a significantly ameliorated liver phenotype, characterized by reduced steatosis and fibrosis, in comparison with separately-housed Vil1creNlrp3fl/fl-MCD mice. This improvement was accompanied by an increased abundance of Faecalibaculum rodentium, a well-known butyrate producer. The in vivo administration of butyrate significantly ameliorated hepatic lipid accumulation and fibrogenesis in Vil1creNlrp3fl/fl-MCD mice. Further, a significant upregulation of activating protein-1 (AP-1) mRNA levels was observed in the liver of Vil1creNlrp3fl/fl-MCD mice, while both co-housed Vil1creNlrp3fl/fl-MCD mice and butyrate administration significantly exhibited downregulated expression of AP-1. Conclusions Deletion of NLRP3 in intestinal epithelial cells leads to a reduction in the abundance of Faecalibaculum rodentium and butyrate production, resulting in the upregulation of hepatic AP-1 expression, thereby exacerbating MASLD.

Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in Mice

Atherosclerotic plaque vulnerability is increased in mouse model of lupus

Antibody against apolipoprotein-A1, non-alcoholic fatty liver disease and cardiovascular risk: a translational study

IDDF2024-ABS-0412 Intestinal NLRP3 Deficiency Aggravates MASLD Mice Via Reduced Butyrate Production

Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF-κB signaling pathway

Hepatocyte-specific Mas Activation Enhances Lipophagy and Fatty Acid Oxidation to Protect Against Acetaminophen-Induced Hepatotoxicity in Mice

Myeloid‐Mas Signaling Modulates Pathogenic Crosstalk among MYC+CD63+ Endothelial Cells, MMP12+ Macrophages, and Monocytes in Acetaminophen‐Induced Liver Injury

Silencing of Hepatic AATF Ameliorates Metabolic Dysfunction Associated Steatohepatitis by Promoting Fatty Acid β-Oxidation in Experimental models

Exploring autoantibodies as predictors of severe fibrosis or cirrhosis in metabolic dysfunction associated with steatotic liver disease

Effects of Therapeutically Approved Individual Bile Acids on The Development of Metabolic Dysfunction-Associated Steatohepatitis a Low Bile Acid Mouse Model

Apob-Containing Lipoproteins Contribute To Augmentation Of Angii-Induced Abdominal Aortic Aneurysms

Roles of Activin A and Gpnmb in metabolic dysfunction-associated steatotic liver disease (MASLD)

Effects of apolipoprotein H downregulation on lipid metabolism, fatty liver disease, and gut microbiota dysbiosis

Antisense oligonucleotide targeting hepatic Serum Amyloid A limits the progression of angiotensin II-induced abdominal aortic aneurysm formation

Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia

PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH

Hepatocytes derived increased SAA1 promotes intrahepatic platelet aggregation and aggravates liver inflammation in NAFLD

Abstract: P1122 EFFECTS OF MACROPHAGE ABCA7 DEFICIENCY ON LIPID METABOLISM AND THE DEVELOPMENT OF ATHEROSCLEROSIS IN LDL RECEPTOR KNOCKOUT MICE

Abstract 466: Metabolome Profile of Experimental Abdominal Aortic Abdominal Aneurysms

Metabonomic Changes Associated with Atherosclerosis Progression for LDLR(-/-) Mice.

Hepatic Amyloid Beta-42-Metabolizing Proteins in Liver Steatosis and Metabolic Dysfunction-Associated Steatohepatitis